NUWE NUWELLIS INC

Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024

Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024

MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) --  Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the first quarter of 2024 on Tuesday, May 7, 2024. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update.

To access the live webcast, please visit the Investors page of the Nuwellis website at . Alternatively, you may access the live conference call by dialing 1-833-816-1404 (U.S) or 1-412-317-0497 (international) and using the conference ID: 10188299. An audio archive of the webcast will be available following the call on the Investors page at .

About Nuwellis

Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit or visit us on or .

About the Aquadex SmartFlow® System 

The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

CONTACTS

INVESTORS:

Vivian Cervantes

Gilmartin Group LLC



EN
30/04/2024

Underlying

NUWENUWELLIS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NUWELLIS INC

 PRESS RELEASE
Free
NUWE NUWELLIS INC

Nuwellis Announces Expansion of Ultrafiltration Program to Pediatric P...

Nuwellis Announces Expansion of Ultrafiltration Program to Pediatric Patients at One of the Largest Hospital Networks in Florida MINNEAPOLIS, May 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the launch of a new pediatric ultrafiltration program utilizing Nuwellis' Aquadex SmartFlow System® at one of the largest health integrated delivery networks (IDN) in Florida. This program marks an expansion by this network to offer ultrafiltration to its pediatric patients, in addition to it...

May 14, 2024 1 EN
 PRESS RELEASE
Free
NUWE NUWELLIS INC

Nuwellis Announces Purchase Agreement with a 50 Hospital Network for A...

Nuwellis Announces Purchase Agreement with a 50 Hospital Network for Aquadex Ultrafiltration Therapy MINNEAPOLIS, May 09, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced a new purchase agreement with one of the top 25 largest integrated delivery networks (IDN) in the U.S. Nuwellis has a successful history of collaborating with individual member hospitals within the IDN on Aquadex utilization. This new network-wide agreement signifies a broader commitment to providing advanced ultrafil...

May 9, 2024 1 EN
 PRESS RELEASE
Free
NUWE NUWELLIS INC

Nuwellis, Inc. Announces First Quarter 2024 Financial Results

Nuwellis, Inc. Announces First Quarter 2024 Financial Results MINNEAPOLIS, May 07, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the first quarter ended March 31, 2024. Highlights: Revenue of $1.9 million, a 2% increase over the prior-year period.Consumables sales, representing 82% of total revenue, grew 11% year-over-year.Pediatric revenue growth of 40% year over year led by a 54% increase in consumable sales.Gross margin of 64.1%, compare...

May 7, 2024 1 EN
 PRESS RELEASE
Free
NUWE NUWELLIS INC

Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pedi...

Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology MINNEAPOLIS, May 02, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid overload, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application related to its innovative pediatric Continuous Renal Replacement Therapy (CRRT) device branded Vivian™. This patent strengthens Nuwellis' intellectual property portfolio and paves the way for the de...

May 2, 2024 1 EN
 PRESS RELEASE
Free
NUWE NUWELLIS INC

Nuwellis Announces Closing of $2.7 Million Public Offering

Nuwellis Announces Closing of $2.7 Million Public Offering MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload, today announced the closing of its previously announced public offering of 11,250,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 16,875,000 shares of its common stock at a combined public offering price of $0.24 per share (or pre-funded warrant in lieu thereof)...

April 30, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch